Retrospective Study of Real-World Treatment Patterns of Subcutaneous Semaglutide Use Among Patients with Metabolic Dysfunction-Associated Steatohepatitis in the United States

Oct 28, 2025ClinicoEconomics and outcomes research : CEOR

Real-World Use of Injected Semaglutide for Patients with Metabolic Liver Disease in the United States

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Of the 6,537 patients with (MASH) treated with high-dose subcutaneous semaglutide, only 7.8% achieved the recommended dosage within the first 16 weeks and maintained it for at least 56 weeks.

in treatment was observed in 68.4% of patients receiving semaglutide and 78.5% in the subgroup receiving the 2.4 mg/week dosage.
The mean time to non-persistence was approximately 24.8 weeks for the overall group and 20.1 weeks for the 2.4 mg/week subgroup.
Among the 2.4 mg/week subgroup, 50.8% of patients reached the target dosage.
Trends in treatment persistence were similar for patients at risk for MASH.

AI simplified

BACKGROUND: Interim results from the ESSENCE clinical trials indicate that 72-week treatment with high-dose subcutaneous (SC) semaglutide may result in (MASH) resolution and improvements in fibrosis. As some patients with MASH have been prescribed SC semaglutide for the treatment of comorbid type 2 diabetes and/or obesity, this study assessed real-world 72-week treatment patterns among patients with MASH.

METHODS: In a linked electronic health records (Veradigm Network EHR) and claims (Komodo Health) dataset, adults (≥18 years old) with a MASH diagnosis, who initiated treatment with SC semaglutide between 7/1/2018 and 6/30/2023, were identified. Other causes of liver disease (eg, viral hepatitis) or severe complications (eg, cirrhosis) were excluded. The study period included ≥52 weeks before and ≥72 weeks after the first SC semaglutide claim. A subgroup analysis was conducted among those who received the brand approved for 2.4 mg/week dosage (SC semaglutide 2.4) and among people at risk for MASH. Patient characteristics and treatment patterns are reported.

RESULTS: This study identified 6,537 patients with MASH, who initiated treatment with SC semaglutide, 358 of whom received only the brand approved for 2.4 mg/week dosage. Patients were ~50 years old, and a majority were female. occurred in 68.4% of the overall SC semaglutide cohort and 78.5% of the SC semaglutide 2.4 subgroup. The mean time to non-persistence was 24.8 (19.3) and 20.1 (16.9) weeks in the SC semaglutide and SC semaglutide 2.4 groups, respectively. In the SC semaglutide 2.4 subgroup, 182 patients (50.8%) reached the recommended dosage of 2.4 mg/week, and 28 (7.8%) reached the recommended dosage within the first 16 weeks and sustained that dosage for ≥56 weeks. Trends were similar among patients at risk for MASH.

CONCLUSION: In a real-world setting, very few patients achieved the treatment regimen associated with MASH resolution and improvements in fibrosis.

Key numbers

68.4%

Rate

Overall cohort

182 of 358

Achieved Recommended Dosage

2.4 mg subgroup

28 of 358

Sustained Dosage for ≥56 Weeks

2.4 mg subgroup

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (PDF) ↗

Retrospective Study of Real-World Treatment Patterns of Subcutaneous Semaglutide Use Among Patients with Metabolic Dysfunction-Associated Steatohepatitis in the United States

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief